|65.06||+0.0900||+0.14%||Vol 1.35M||1Y Perf 57.73%|
|Nov 29th, 2023 16:00 DELAYED|
|- -%||- -|
|Target Price||61.09||Analyst Rating||Strong Buy 1.35|
|Potential %||-6.10||Finscreener Ranking||★★★ 49.58|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★ 45.74|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★ 39.68|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||40.52||Earnings Rating||Strong Buy|
|Market Cap||11.77B||Earnings Date||1st Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.49|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||687.65K|
|Avg. Monthly Volume||1.51M|
|Avg. Quarterly Volume||1.38M|
Exact Sciences Corporation (NASDAQ: EXAS) stock closed at 65.06 per share at the end of the most recent trading day (a 0.14% change compared to the prior day closing price) with a volume of 1.35M shares and market capitalization of 11.77B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 5000 people. Exact Sciences Corporation CEO is Kevin T. Conroy.
The one-year performance of Exact Sciences Corporation stock is 57.73%, while year-to-date (YTD) performance is 31.41%. EXAS stock has a five-year performance of -16.57%. Its 52-week range is between 40.73 and 100.77, which gives EXAS stock a 52-week price range ratio of 40.52%
Exact Sciences Corporation currently has a PE ratio of -11.50, a price-to-book (PB) ratio of 2.70, a price-to-sale (PS) ratio of 6.83, a price to cashflow ratio of 364.30, a PEG ratio of -0.22, a ROA of -12.00%, a ROC of -12.34% and a ROE of -23.73%. The company’s profit margin is -32.38%, its EBITDA margin is -26.00%, and its revenue ttm is $1.53 Billion , which makes it $8.62 revenue per share.
Of the last four earnings reports from Exact Sciences Corporation, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.49 for the next earnings report. Exact Sciences Corporation’s next earnings report date is -.
The consensus rating of Wall Street analysts for Exact Sciences Corporation is Strong Buy (1.35), with a target price of $61.09, which is -6.10% compared to the current price. The earnings rating for Exact Sciences Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Exact Sciences Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Exact Sciences Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.93, ATR14 : 2.84, CCI20 : 68.38, Chaikin Money Flow : -0.10, MACD : 0.03, Money Flow Index : 39.74, ROC : 9.09, RSI : 50.97, STOCH (14,3) : 61.22, STOCH RSI : 0.04, UO : 38.32, Williams %R : -38.78), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Exact Sciences Corporation in the last 12-months were: Brian Baranick (Sold 0 shares of value $0 ), Brian Baranick (Sold 2 770 shares of value $170 643 ), Condella Sarah (Option Excercise at a value of $0), Condella Sarah (Sold 21 574 shares of value $1 562 325 ), Conroy Kevin (Option Excercise at a value of $0), Conroy Kevin (Sold 34 324 shares of value $2 186 371 ), Coward D. (Option Excercise at a value of $0), Coward D. (Sold 6 981 shares of value $436 430 ), Cunningham Everett (Sold 0 shares of value $0 ), Cunningham Everett (Sold 16 635 shares of value $1 089 808 ), Doyle James (Option Excercise at a value of $90 480), Doyle James (Sold 3 402 shares of value $288 135 ), Doyle James Edward (Sold 2 000 shares of value $194 840 ), Elliott Jeffrey (Option Excercise at a value of $0), Elliott Jeffrey (Sold 8 687 shares of value $545 550 ), Everett V. Cunningham (Option Excercise at a value of $0), Everett V. Cunningham (Sold 3 628 shares of value $224 972 ), Herriott James (Sold 1 300 shares of value $130 000 ), James E. Doyle (Option Excercise at a value of $90 480), James Herriott (Option Excercise at a value of $0), James Herriott (Sold 3 023 shares of value $185 652 ), Jeffrey T. Elliott (Option Excercise at a value of $0), Jeffrey T. Elliott (Sold 8 687 shares of value $545 550 ), Kevin T. Conroy (Option Excercise at a value of $0), Kevin T. Conroy (Sold 34 324 shares of value $2 186 371 ), Napier Katherine (Sold 3 027 shares of value $273 974 ), Orville Jacob (Option Excercise at a value of $0), Orville Jacob (Sold 20 496 shares of value $1 373 232 ), Sarah Condella (Option Excercise at a value of $0), Sarah Condella (Sold 8 987 shares of value $564 035 ), Scott D. Coward (Option Excercise at a value of $0), Scott D. Coward (Sold 6 981 shares of value $436 430 )
Tue, 28 Nov 2023 13:20 GMT Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Exact Sciences (EXAS) and Regeneron (REGN)- TipRanks. All rights reserved.
Tue, 31 Oct 2023 10:55 GMT Exact Sciences (EXAS) Receives a Hold from Benchmark Co.- TipRanks. All rights reserved.
Mon, 23 Oct 2023 13:10 GMT Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Elevance Health (ELV)- TipRanks. All rights reserved.
Wed, 02 Aug 2023 14:40 GMT Analysts Top Healthcare Picks: Exact Sciences (EXAS), IQVIA Holdings (IQV)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.